RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay
RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing
RareCyte® expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit.
RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.
“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”
– Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company